Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VistaGen presents positive pain drug data
The preclinical studies suggest that AV-101, a first-in-class prodrug, has the potential to treat pain caused by nerve damage associated with diabetes, viral infections, injuries and cancer. VistaGen
The preclinical studies suggest that AV-101, a first-in-class prodrug, has the potential to treat pain caused by nerve damage associated with diabetes, viral infections, injuries and cancer. VistaGen
This trial will enroll peripheral T-cell lymphoma (PTCL) patients who have progressed or become refractory following systemic therapy. A special protocol assessment is a request for feedback from
Encore's drug, known as ETI-211, is designed for post-surgical pain management; to reduce opiate use and possibly shorten hospital stays. The preclinical studies demonstrated a dose-dependant analgesic effect
Immtech said that it plans to apply to the World Health Organization (WHO) to have pafuramidine designated as a WHO recommended drug, so that pafuramidine could be made
As a safety precaution, the FDA classifies prescription drugs with specific category ratings to provide guidelines for physicians treating pregnant women. NovoLog has now been given a pregnancy
<p>This vaccine utilizes GSK's adjuvant system technology which allows a very low amount of antigen to be used to elicit a strong seroprotective response.<br /><br />In a recent
The study suggested that BioVant may serve as a vaccine adjuvant for the development of an effective vaccine against H5N1 avian flu. The objective of BioSante's preclinical study
Hydase will be manufactured by PrimaPharm, which owns its new drug application. Hydase' formulation is preservative free and does not contain thimerosal, a mercury-containing agent. Akorn will have
Alfacell is evaluating Onconase in a confirmatory phase IIIb clinical trial in unresectable malignant mesothelioma. Orphan drug designation permits Alfacell to be awarded seven years of marketing exclusivity
The jury decided that Wyeth failed to adequately warn the patient of the risks involved with the treatment. They also found that Wyeth acted with malice or reckless